-
Mertansine, also
called DM1 (and in some of its
forms emtansine), is a thiol-containing
maytansinoid that for
therapeutic purposes is
attached to a monoclonal...
-
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It
comprises the CD56-binding antibody,
lorvotuzumab (huN901), with a
maytansinoid cell-killing...
-
Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug
conjugate investigated to
treat colorectal cancer and
other types of cancer. It is a...
-
Bivatuzumab mertansine is a
combination of bivatuzumab, a
humanized monoclonal antibody, and
mertansine, a
cytotoxic agent. It is
designed for the treatment...
-
several cytotoxic agents,
yielding antibody-drug conjugates :
Cantuzumab mertansine Cantuzumab ravtansine "HuC242
binds to the
extracellular domain of the...
- (INN)
bitolterol (INN)
bitoscanate (INN)
bivalirudin (INN)
bivatuzumab mertansine (INN)
Bivigam bixalomer (USAN, INN)
bizelesin (INN)
Bizengri Bkemv Blenoxane...
- It uses a more
hindered disulfide linkage than
cantuzumab mertansine.
Cantuzumab mertansine ImmunoGen Inc,
developer of DM4
based drugs World Health Organization...
-
inhibitors monomethyl auristatin E (MMAE),
monomethyl auristatin F (MMAF) and
mertansine, DNA
binder calicheamicin and
topoisomerase 1
inhibitors SN-38 and exatecan...
-
Kadcyla DM1
attached to an
antibody with ImmunoGen's SPP
linker is
called "
mertansine". DM4
attached with ImmunoGen's SPDB
linker is
called "ravtansine" indatuximab...
- approval. It
consists of
trastuzumab (Herceptin)
linked to a
cytotoxic agent mertansine (DM1), used in the
treatment of HER2-positive
metastatic breast cancer...
